Skip to content

Uridine monophosphate and memory: grade C

Limited evidence. Direction: No effect.

Evidence maturity: EstablishedIndustry-funded

Why this grade

Rubric condition met: C: results only in clinical populations being extrapolated to healthy adults; every memory RCT found used a multinutrient drink (UMP with omega-3s, choline, B vitamins and more) in people with Alzheimer's disease; no RCT of uridine alone in healthy adults

Every controlled human memory trial found tested Souvenaid (Fortasyn Connect), a drink combining UMP with omega-3 fats, choline, B vitamins and other nutrients, in people with Alzheimer's disease, so no effect can be attributed to uridine and results may not apply to healthy adults. Two manufacturer-funded trials in mild disease reported memory gains, but a Cochrane review of three low-risk-of-bias trials judged that it probably makes little or no difference to cognitive function. A small pilot RCT in children using a DHA, vitamin D3 and uridine supplement could not show a cognitive effect; 14 of 16 children completed and its own power calculation called for 26. Animal work in gerbils supports the mechanism only. The best synthesis, a Cochrane review, found probably little or no difference in global or specific cognitive functions, so the direction is none (limited, mixed) rather than benefit.

How sure are we?

Evidence maturity: Established Established for the Souvenaid multinutrient drink in Alzheimer's disease (Cochrane review of 3 low-risk trials); for uridine itself, Mechanistic only.

Tested as: Uridine monophosphate inside the Souvenaid multinutrient drink

Who paid for the studies
All industry-funded
Risk of bias
Low. Every Souvenaid trial is manufacturer-linked (Nutricia).
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Material tested
Within a multinutrient drink (Souvenaid)
Rules applied
Population cap (logged, no further change): Alzheimer's disease; Combination only (logged, no further change): Multinutrient drink only; B2: one funder or group (logged, no further change): One manufacturer behind every trial
  • Could rise: Would move to C benefit for uridine alone with a preregistered RCT of uridine or UMP alone, of adequate size, positive on a memory primary outcome.
  • Could fall: Would move to N for the drink if a second Cochrane-quality synthesis restricted to low-risk trials were null.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.

Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
Traditional use only
a traditional-use monograph and nothing else

How we grade evidence

Studies this grade rests on

EffectMixedNo effectSize shows participants (n)20052010201520202025Systematic reviewRCTAnimal study (ger…Burckhardt 2020, 2020: systematic review, n = 1,097, result not recordedSoininen 2021, 2021: RCT, n = 311, result not recordedScheltens 2010, 2010: RCT, n = 225, result not recordedOlde 2015, 2015: RCT, n = 201, result not recordedHansen 2017, 2017: RCT, n = 16, result not recordedHolguin 2008, 2008: animal study (gerbils), n not recorded, result not recordedScheltens 2012, 2012: RCT, n not recorded, result not recorded
each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.
Show the numbers
StudyYearDesignParticipantsResult
Holguin 20082008animal study (gerbils)not recordedresult not recorded
Scheltens 20102010RCT225result not recorded
Scheltens 20122012RCTnot recordedresult not recorded
Olde 20152015RCT201result not recorded
Hansen 20172017RCT16result not recorded
Burckhardt 20202020systematic review1097result not recorded
Soininen 20212021RCT311result not recorded

Supplementation of docosahexaenoic acid (DHA), vitamin D(3) and uridine in combination with six weeks of cognitive and motor training in prepubescent children: a pilot study.

Hansen SL, Ritterband-Rosenbaum A, Voigt CB. Supplementation of docosahexaenoic acid (DHA), vitamin D(3) and uridine in combination with six weeks of cognitive and motor training in prepubescent children: a pilot study BMC Nutr, 2017. PMID 32153817

Result not recorded
Design
Randomized, placebo-controlled, double-blind pilot trial (6 weeks)
Sample
n = 16
Population
Prepubescent children aged 8-11
Funding
Elsass Foundation (Crossref funder list)

Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils.

Holguin S, Martinez J, Chow C. Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils FASEB J, 2008. PMID 18606862

Result not recorded
Design
Animal study (gerbils)
Population
Normal adult gerbils
Funding
NIMH NIH HHS MH-28283, National Institutes of Health

Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study.

Olde Rikkert MG, Verhey FR, Blesa R. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study J Alzheimers Dis, 2015. PMID 25322923

Result not recorded
Design
24-week open-label extension of a randomized trial (Souvenir II OLE)
Sample
n = 201
Population
Adults with mild Alzheimer's disease (clinical population)
Funding
not stated in PubMed record; an author is affiliated with Nutricia Research

36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease.

Soininen H, Solomon A, Visser PJ. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease Alzheimers Dement, 2021. PMID 32920957

Result not recorded
Design
Randomized, double-blind, placebo-controlled trial (36 months), LipiDiDiet
Sample
n = 311
Population
Adults with prodromal Alzheimer's disease (clinical population)
Funding
European Research Council; Academy of Finland (Crossref); EU grants; Danone Nutricia Research funded months 25-96 (COI statement)

Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial.

Scheltens P, Twisk JW, Blesa R. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial J Alzheimers Dis, 2012. PMID 22766770

Result not recorded
Design
Randomized, controlled, double-blind, parallel-group trial (24 weeks), Souvenir II
Population
Drug-naive adults with mild Alzheimer's disease (clinical population)
Funding
Manufacturer of Souvenaid, per the Cochrane review (S8)

Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial.

Scheltens P, Kamphuis PJ, Verhey FR. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial Alzheimers Dement, 2010. PMID 20129316

Result not recorded
Design
Randomized, double-blind, controlled trial (12 weeks), Souvenir I
Sample
n = 225
Population
Drug-naive adults with mild Alzheimer's disease (clinical population)
Funding
Danone Research Centre for Specialised Nutrition (Crossref funder list)

Souvenaid for Alzheimer's disease.

Burckhardt M, Watzke S, Wienke A. Souvenaid for Alzheimer's disease Cochrane Database Syst Rev, 2020. PMID 33320335

Result not recorded
Design
Cochrane systematic review of 3 randomized, placebo-controlled trials
Sample
n = 1,097
Population
People with prodromal Alzheimer's disease or mild to mild-to-moderate Alzheimer's dementia (clinical population)
Funding
not stated in PubMed record; authors declare no known COI

Search and history

Search (): (Souvenaid[tiab] OR "Fortasyn Connect"[tiab]) AND randomized controlled trial[pt]; uridine[ti] AND (cognition[tiab] OR cognitive[tiab] OR memory[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) AND humans[mh]

  • Graded C (awaiting approval)
  • C to C (awaiting approval): The combination rule puts the multinutrient-drink context on the grade; direction changed from benefit to none because the Cochrane review of three low-risk-of-bias trials found probably little or no difference and the only healthy-population trial (children) could not show an effect but was underpowered by its own calculation (14 of 16 completed, 26 needed), so it adds little either way, while the positive memory results come from manufacturer-funded trials.
  • C to C (awaiting approval) (maturity: established): Maturity, bias summary and re-check date added
  • C to C (approved) (maturity: established): Editor sign-off November 16, 2026: grade matches the editor-approved final page